These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 3097632)
1. [Effect of rifampicin on the L transformation of a mycobacterial population in patients with destructive pulmonary tuberculosis]. Karachunskiĭ MA; Dorozhkova IR; Chukanov VI; Balta IuE; Kiazimova LM Probl Tuberk; 1986; (9):31-4. PubMed ID: 3097632 [No Abstract] [Full Text] [Related]
2. [L-transformation of the mycobacterial population in the process of treating patients with newly detected destructive pulmonary tuberculosis]. Khomenko AG; Karachunskiĭ MA; Dorozhkova IR; Chukanov VI; Balta IuE Probl Tuberk; 1980 Feb; (2):18-23. PubMed ID: 6769110 [No Abstract] [Full Text] [Related]
3. [Clinical significance of finding mycobacterial L forms in patients with destructive pulmonary tuberculosis]. Golanov VS Probl Tuberk; 1986; (9):25-8. PubMed ID: 3097630 [No Abstract] [Full Text] [Related]
4. [Characteristics of a Mycobacterium population growing in pulmonary tuberculomas]. Dorozhkov IR; Karachunskiĭ MA; Kiazimova LG Probl Tuberk; 1987; (4):46-50. PubMed ID: 3110766 [No Abstract] [Full Text] [Related]
5. [Clinical picture and course of chronic destructive pulmonary tuberculosis in patients secreting L forms of the causative agent]. Karachunskiĭ MA; Dorozhkova IR; Abdullaeva ET Probl Tuberk; 1985; (12):13-6. PubMed ID: 3938018 [No Abstract] [Full Text] [Related]
6. [Clinical significance of drug resistance of tuberculosis mycobacteria and L-forms]. Golanov VS; Bogdalova VE; Andreev LP; Losin EI; Ushakova AG; Meshcheriakov VG; Bondin SV Probl Tuberk; 1991; (12):27-8. PubMed ID: 1803368 [TBL] [Abstract][Full Text] [Related]
7. [Characteristics of the course of destructive pulmonary tuberculosis with L-forms of mycobacteria in the sputum]. Golanov VS Vrach Delo; 1981 Aug; (8):79-81. PubMed ID: 6791384 [No Abstract] [Full Text] [Related]
8. [L-forms of Mycobacterium tuberculosis during chemotherapy of patients with chronic destructive pulmonary tuberculosis]. Karachunskiĭ MA; Dorozhkova IR; Kaminskaia AA; Abdullaeva ET Probl Tuberk; 1983 Jul; (7):38-43. PubMed ID: 6415651 [No Abstract] [Full Text] [Related]
9. [Bacteriological relapse among the previously treated advanced pulmonary tuberculosis patients whose sputum converted to negative by the rifampicin treatment, with special reference to the duration of rifampicin administration (author's transl)]. Yamamoto M; Morishita M; Hirano Y; Nagata A; Yazaki M Kekkaku; 1974 Jul; 49(7):195-9. PubMed ID: 4214961 [No Abstract] [Full Text] [Related]
10. [Mycobacterium tuberculosis L forms in patients with abacillary lung caverns]. Berezovskiĭ BA; Golanov VS Probl Tuberk; 1981 Jun; (6):22-5. PubMed ID: 6792625 [No Abstract] [Full Text] [Related]
11. [The composition and drug sensitivity of a mycobacterial population in patients with suspected tuberculosis]. Dorozhkova IR; Badleeva MV; Skotnikova OI; Nosova EIu; Kupavtseva EA; Borisov SE; Moroz AM Probl Tuberk Bolezn Legk; 2005; (8):36-8. PubMed ID: 16209018 [TBL] [Abstract][Full Text] [Related]
12. [Dynamics of the excretion of the bacilli in patients with destructive pulmonary tuberculosis under the effect of long-term tuberculostatic therapy]. Fisher EF; Velichko SA; Sharaburova OE; Strelis AK Lab Delo; 1973; 6():340-2. PubMed ID: 4129386 [No Abstract] [Full Text] [Related]
13. [L forms of Mycobacterium tuberculosis and their clinico-epidemiological significance]. Anastasatu C; Moldovan O Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1985; 34(3):203-13. PubMed ID: 3001898 [No Abstract] [Full Text] [Related]
14. [Chemotherapy of patients with chronic destructive pulmonary tuberculosis in cases of mycobacterial resistance to rifampicin and isoniazid]. Bialik IB; Klimenko MT Klin Med (Mosk); 1985 Dec; 63(12):42-7. PubMed ID: 3937942 [No Abstract] [Full Text] [Related]
15. [Increasing the effectiveness of microbiological diagnosis of limited nondestructive pulmonary tuberculosis]. Gamzaeva NF; Dorozhkova IR; Karachunskiĭ MA Probl Tuberk; 1989; (2):55-7. PubMed ID: 2495528 [No Abstract] [Full Text] [Related]
16. [Endogenous reactivation of tuberculosis as a result of reversion of persistent mycobacterial L-forms]. Dorozhkova IR; Zemskova ZS; Krudu VN; Kochetkova EIa Probl Tuberk; 1995; (3):43-6. PubMed ID: 7617636 [TBL] [Abstract][Full Text] [Related]
17. [Rifampicin in the treatment of patients with chronic destructive tuberculosis complicated by drug intolerance and Mycobacterium drug resistance]. Adamovich VN; Kolomytseva OS; Gur'ian IE Vrach Delo; 1975 Jan; (1):95-9. PubMed ID: 806177 [No Abstract] [Full Text] [Related]
18. [Mycobacterium tuberculosis L forms in patients with pulmonary and pleural tuberculosis during antibacterial chemotherapy]. Osiĭskiĭ IIu; Kotliar KD Vrach Delo; 1989 Sep; (9):55-6. PubMed ID: 2514488 [No Abstract] [Full Text] [Related]
19. [Dynamics of L-form Mycobacteria excretion in the treatment of patients with newly diagnosed destructive pulmonary tuberculosis]. Karachunskiĭ MA; Dorozhkova IR; Balta IuE Probl Tuberk; 1978 Mar; (3):66-70. PubMed ID: 418400 [No Abstract] [Full Text] [Related]
20. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Diacon AH; Patientia RF; Venter A; van Helden PD; Smith PJ; McIlleron H; Maritz JS; Donald PR Antimicrob Agents Chemother; 2007 Aug; 51(8):2994-6. PubMed ID: 17517849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]